Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance

Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study. However, resistance inevitably hinders patient prognosis, increasing the need for new therapeutic strategies beyond osimert...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Taisuke, Kanda, Shintaro, Horinouchi, Hidehito, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Review Article (Invited)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311169/
https://www.ncbi.nlm.nih.gov/pubmed/37279591
http://dx.doi.org/10.1093/jjco/hyad052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311169/
https://www.ncbi.nlm.nih.gov/pubmed/37279591
http://dx.doi.org/10.1093/jjco/hyad052

Ejemplares similares